AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03158740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health education control
Description: The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
Study NCT03580278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035/AFO2
Description: Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
Study NCT03082911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.
Study NCT03082911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation letter
Description: The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
Study NCT03082911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation letter
Description: The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
Study NCT02425956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Optima/Discovery® MRI data of the liver
Description: GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
Study NCT04154293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Topical Isotretinoin ointment
Study NCT04154293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical Vehicle Ointment
Study NCT05734911 — intervention group
Intervention type: DRUG
Intervention: Niraparib
Description: We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
Study NCT02455336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
Study NCT02455336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
Study NCT02177331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone/formoterol
Description: 2 puffs bid for first 5 weeks in each treatment arm
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol
Description: 2 puffs bid for first 5 weeks in each treatment arm
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 1 puff daily for first 4 weeks of each treatment arm
Study NCT01656005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 1 puff daily for first 4 weeks of each treatment arm
Study NCT06507891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets
Description: TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
Study NCT06507891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets + Anlotinib capsules
Description: TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study NCT02790528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20mg QD
Study NCT02790528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug will be administered.
Study NCT00109798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Patient will take drug on day 1-5 of 28 day schedule
Study NCT00109798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Patient will have IV on days 2-6 on a 28-day schedule
Study NCT02888886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires about food habits and tobacco
Study NCT02888886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry
Study NCT02888886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid echography
Study NCT02888886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
Study NCT01525537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of sufentanil
Description: 10 microgram sufentanil were given when SPI above 50 for more then 20 sec
Study NCT01525537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: sufentanil was given at standard practise
Study NCT03633682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
Study NCT03633682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Headspace - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
Study NCT03633682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Breathe, & Think - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
Study NCT03633682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stop, Breathe, & Think - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
Study NCT02279420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: g-Cath EZ™ Suture Anchor Delivery Catheter
Description: This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
Study NCT03876444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone
Description: Intravenous Methylprednisolone will be used in the intervention group
Study NCT03876444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Pednisolone
Description: Oral Prednisolone will be used in the Control Group
Study NCT00089245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine I 131 MOAB 8H9
Description: Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
Study NCT00089245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine I 131 MOAB 8H9
Description: The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
Study NCT01938677 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Initial Gamma knife radiosurgery
Study NCT01765088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
Study NCT01765088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
Study NCT01765088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-IFN
Description: 3mIU (3million) D1，3，5
Study NCT00578812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Description: Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study NCT00578812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Description: PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study NCT00471068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travatan
Description: Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
Study NCT00471068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
Study NCT00471068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Timolol Vehicle)
Description: Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
Study NCT02681562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Study NCT04188327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours
Study NCT04188327 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stellate ganglion block
Description: The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours
Study NCT03954925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic anterior cruciate ligament with short hamstring graft technique
Description: ACL and short hamstring graft
Study NCT03954925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic anterior cruciate ligament with a standard hamstring graft technique
Description: ACL with standard hamstring graft
Study NCT00542425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 20 µg
Description: BA058 20 µg subcutaneous daily
Study NCT00542425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 40 µg
Description: BA058 40 µg subcutaneous daily
Study NCT00542425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 80 µg
Description: BA058 80 µg subcutaneous daily
Study NCT01393704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Study NCT01797653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CPAP therapy withdrawal
Description: CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
Study NCT01797653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continue CPAP treatment
Description: Continue treatment with therapeutic continuous positive airway pressure device
Study NCT02673437 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study NCT03629132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma intrauterine injection
Study NCT03629132 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: gel
Description: Self-crosslinking sodium hyaluronate gel intrauterine injection
Study NCT03141476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 1,5g
Description: Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
Study NCT03141476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 3g
Description: Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
Study NCT03141476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 4,5g
Description: Patients with BMI of >50kg/m\*m: 4,5 g Cefuroxime
Study NCT03535844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wolfberry
Description: Consumption of cooked dehydrated wolfberry as part of a mixed meal.
Study NCT03535844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet
Description: Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
Study NCT03535844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy diet
Description: Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
Study NCT04847492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
Study NCT04847492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
Study NCT02891759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloderm RTU
Description: -Most commonly used acellular dermal matrices
Study NCT02891759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cortiva 1mm Allograft Dermis
Description: -Tutoplast processed dermis
Study NCT02891759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin or nipple-sparing mastectomy
Description: -Standard of care
Study NCT02891759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Q
Description: * 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time
Study NCT02891759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: * To address the tissue expander~* Standard of care
Study NCT02345629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sharpness Sensory Testing
Description: Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
Study NCT02345629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sharpness Sensory Testing
Description: Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
Study NCT02345629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Pain Sensory Testing
Description: Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
Study NCT00688974 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass
Study NCT00688974 — intervention group
Intervention type: PROCEDURE
Intervention: Adjustable gastric band
Description: Laparoscopic adjustable gastric band
Study NCT00590031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
Study NCT00590031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be given 65 mg/m2
Study NCT00590031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: will be delivered with multiple (>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.